Table 3. Monoclonal Antibodies studied in Ovarian Cancer.
| Antibody | Target | Reference | Phase | Clinical Response | Immune Response |
|---|---|---|---|---|---|
| Oregovomab |
CA125 |
49 |
II |
3 SD 10 PD |
Oregovomab and CA125-specific antibody and T cell responses |
| |
|
50 |
I |
4 NED 2 CR 7 PD |
HAMA, anti-oregovomab and anti-CA125 antibodies |
| Abagovomab |
CA125 |
53 |
I |
NA |
HAMA, anti-anti-idiotypic and antiCA125 antibodies, CA125-specific CD4 and CD8 T cells |
| |
|
54 |
Ib/II |
4 CR 30 SD 62 PD 23 NA |
Anti-anti-idiotypic and antiCA125 antibodies, Antibody dependent cell-mediated cytotoxicity |
| |
|
55 |
I |
12 SD 21 PD |
HAMA and anti-anti-idiotypic antibodies, CA125-specific IFN-γ producing T cells |
| HMFG1 |
MUC1 |
56 |
I |
1 SD 25 RD |
Anti-HMFG1 and anti-MUC1 antibodies |
| Catumaxomab |
EpCAM, CD3 |
60,61 |
II/III |
Longer puncture-free survival and time to next paracentesis |
Human anti-mouse antibodies |
| Trastuzamab |
HER2/neu |
63 |
II |
1 CR 2 PR 16 SD 22 PD |
No anti-trastuzumab antibody formation |
| MOv18 |
FR-α |
65 |
I |
NA |
No anti-c-MOv18 antibodies |
| MORAb-003 |
FR-α |
66 |
I |
9 SD 16 PD 1 NE |
Limited anti-MORAb-003 antibodies |
| Bevacizumab |
VEGF |
69 |
II |
2 CR 11 PR 32 SD 17 PD |
NA |
| |
|
70 |
II |
0 CR 7 PR 27 SD 5 PD 5 NE |
NA |
| |
|
67 |
III |
168 Responders (CR/PR) 82 Non-responders (SD/PD) 7 unknown |
NA |
| 68 | III | No difference in OS; significant improval in PFS | NA |
SD, stable disease; PD, progressive disease; NED, no evidence of disease; CR, complete response; HAMA, human anti-mouse antibody; NA, not available; RD, recurrent disease; NE, not evaluable